SCHEMBL13283263

SCHEMBL13283263

COCCNc1ncnc2ccc(Br)cc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.72
CCNC P24863 1/20 0.72
CDK8 P49336 1/20 0.72
LMNA P02545 8/20 0.68
MAPT P10636 1/20 0.68
LDHA P00338 1/20 0.68
ALDH1A1 P00352 12/20 0.64
CYP1A2 P05177 10/20 0.64
CYP3A4 P08684 10/20 0.64
CLK4 Q9HAZ1 9/20 0.64
CYP2C19 P33261 6/20 0.64
CYP2D6 P10635 6/20 0.64
USP2 O75604 3/20 0.64
MAPK1 P28482 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
HSD17B10 Q99714 8/20 0.62
TSHR P16473 4/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
ALOX15 P16050 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14300930 0.92 LMNA (0.76) HTTCCNCCDK8LMNAMAPT
SCHEMBL13283184 0.86 LMNA (0.85) HTTCCNCCDK8LMNALDHA
SCHEMBL14300974 0.85 HTT (0.75) HTTCCNCCDK8LMNAMAPT
SCHEMBL6672212 0.84 ALDH1A1 (0.76) HTTLMNAMAPTLDHAALDH1A1
SCHEMBL4359487 0.84 HTT (1.00) HTTCCNCCDK8LMNAMAPT
SCHEMBL13283187 0.82 LMNA (0.75) HTTCCNCCDK8LMNAMAPT
SCHEMBL4359385 0.81 HTT (0.83) HTTCCNCCDK8LMNAMAPT
SCHEMBL11246544 0.81 LDHA (1.00) HTTLMNAMAPTLDHAALDH1A1
SCHEMBL13874409 0.81 HTT (0.73) HTTCCNCCDK8LMNAMAPT
SCHEMBL5076850 0.81 LMNA (1.00) HTTCCNCCDK8LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190807-A1 CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein SENEX BIOTECHNOLOGY, INC. 2010-07-29 US disclosed
US-20090281129-A1 CDKI PATHWAY INHIBITORS AND USES THEREOF SENEX BIOTECHNOLOGY, INC. 2009-11-12 US disclosed
US-20080033000-A1 Identification of CDKI pathway inhibitors SENEX BIOTECHNOLOGY, INC. 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190807-A1 CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein MAPT, CDK5, CDKN1A HTT 292/4885CCNC 89/4885CDK8 13/4885
US-20090281129-A1 CDKI PATHWAY INHIBITORS AND USES THEREOF CDKN1A, CDK6, CCNI HTT 930/4885CCNC 32/4885CDK8 9/4885
US-20080033000-A1 Identification of CDKI pathway inhibitors CDKN1A, CDK6, CDK2 HTT 1550/4885CCNC 36/4885CDK8 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.